With its Covid-19 monoclonal antibody sidelined in the US since April and plans for full approval no longer in the cards, Vir Biotechnology is putting more eggs into the influenza basket with a hefty-sized contract from the federal government.
A capital infusion will bankroll a US-only Phase II testing…
